

1 **Mapping Patient-Reported Outcomes**  
2 **to EQ-5D Utilities in Hand Surgery:**  
3 **Development and Evaluation of**  
4 **Algorithms**

5  
6 Luke Geoghegan L<sup>1</sup>, Conrad J Harrison<sup>2</sup>, Shehan Hettiaratchy <sup>3</sup>, Jeremy N  
7 Rodrigues<sup>4,5</sup>

8  
9 <sup>1</sup> *Department of Surgery and Cancer, Imperial College London. London, UK*

10 <sup>2</sup> *Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of*  
11 *Oxford. Oxford, UK*

12 <sup>3</sup> *Department of Plastic Surgery, St Mary's Hospital, Imperial College Healthcare NHS Trust. London,*  
13 *UK.*

14 <sup>4</sup> *Department of Plastic and Reconstructive Surgery, Stoke Mandeville Hospital. Aylesbury, UK.*

15 <sup>5</sup> *Warwick Clinical Trials Unit, University of Warwick. Coventry, UK.*

16

17

18 **Corresponding author**

19 Prof. Jeremy Rodrigues

20 Warwick Clinical Trials Unit

21 University of Warwick

22 Coventry

23 UK

24 Tel: +44 (0) 2476 574 880

25 Email: jeremy.rodrigues1@nhs.net

26

27 **Declaration of competing interests:** The authors declared no potential conflicts  
28 of interest with respect to the research, authorship, and/or publication of this article.

29

30 **Funding statement:** Conrad J. Harrison is funded by a National Institute for Health  
31 Research (NIHR) Doctoral Research Fellowship (NIHR300684). Jeremy N. Rodrigues is  
32 funded by a NIHR postdoctoral fellowship (PDF-2017-10-075). This document  
33 presents independent research funded by the NIHR. The views expressed are those  
34 of the authors and not necessarily those of the NHS, the NIHR or the Department of  
35 Health and Social Care.

36

37 **Category:** Original article

38

39

40 **ABSTRACT**

41 Health state utility values (HSUVs) describe the desirability of health  
42 states and are needed to calculate quality-adjusted life years.  
43 Traditionally, HSUVs are derived using generic measures such as the EQ-  
44 5D. No hand-specific measures can be used to derive HSUVs. This study  
45 aimed to develop and evaluate mapping algorithms to estimate the EQ-5D  
46 utility index from the Patient Evaluation Measure (PEM). Matched PEM and  
47 EQ-5D-5L data from 2043 patients were used to develop mapping  
48 algorithms. Transfer-to-utility models were developed and assessed  
49 through 1000-fold bootstrap validation. The Tobit censored regression  
50 model had the lowest mean absolute error of 0.127. We present a range of  
51 mapping algorithms to derive HSUVs from a commonly used hand-specific  
52 PROM. The population-level prediction error of our best performing models  
53 was clinically relevant. This suggests that mapping hand-specific PROMs  
54 onto generic preference-based measures may not be appropriate. Future  
55 work could seek to develop hand-specific preference-based measures.

56

57 **Level of evidence: II**

58

59

## 60 **INTRODUCTION**

61 Budget constrained healthcare systems must operate equitably to optimise  
62 outcomes for patients. The current tax-funded, free at the point of use healthcare  
63 model adopted by the UK National Health Service (NHS) requires complex resource  
64 allocation decisions to be made to ensure financial stability (Barr et al., 2014).  
65 Policymakers must ensure that appropriate valuation techniques are used to  
66 appraise interventions.

67

68 Quality-adjusted life years (QALYs) have emerged as a metric that enables life years  
69 to be adjusted to reflect health experienced during those life years (Lizan Tudela et  
70 al., 2009). The quality component of QALYs is known as the 'utility value' associated  
71 with a given health state. Utilities are typically scaled from 0 (equivalent to instant  
72 death) to 1 (equivalent to full health) (Raisch, 2000). The number of QALYs relating  
73 to a specific health state is expressed as the utility value of a given health state  
74 multiplied by the length of time in a given health state. Multi-attribute utility scales,  
75 such as the EuroQol five dimension (EQ-5D), are commonly used to estimate utilities.  
76 The EQ-5D has generic health classification system and a set of utility values  
77 assigned to each health state described (Herdman et al., 2011). It is widely accepted  
78 by policy makers and is the preferred preference-based instrument for technology  
79 appraisal in the UK (NICE, 2013).

80

81 Where EQ-5D utilities for a health state are not available, NICE recommend that  
82 utilities are derived by mapping available outcome measures onto preference-based  
83 PROMs such as the EQ-5D (NICE, 2013). The use of mapping algorithms in  
84 technology appraisal has grown substantially. A recent systematic review identified  
85 144 mapping studies reporting 190 models from 110 distinct source outcome  
86 measures (Dakin et al., 2018). Mapping to predict EQ-5D utilities is of particular  
87 relevance in hand surgery, where hand-specific outcome measures predominate.

88 Less than 5% of published studies reported the use of preference-based measures  
89 (such as the EQ-5D), meaning cost-utility analyses cannot be performed using  
90 existing data (Lloyd-Hughes et al., 2019).

91

92 The paucity of primary utility data for hand conditions may mean that interventions  
93 are undervalued when cost-utility analyses are performed. This study aimed to  
94 develop and evaluate mapping models in the prediction of EQ-5D-5L utility scores  
95 from a commonly used hand-specific PROM, the Patient Evaluation Measure (PEM).  
96 The use of mapping algorithms may increase the availability of EQ-5D data available  
97 for cost utility analysis, meaning that novel and existing interventions for hand  
98 conditions can be accurately appraised.

## 99 **METHODS**

100 This study was conducted and is reported in line with the Mapping onto Preference-  
101 based measures reporting Standards (MAPS) statement (Petrou et al., 2015). This  
102 study used data from the UK Hand Registry (UKHR). The UKHR is a national voluntary  
103 registry for all patients undergoing elective intervention for hand and wrist  
104 conditions. Patients included in the UKHR are asked to complete both the EQ-5D-5L  
105 and the Patient Evaluation Measure (PEM) at baseline and 3, 6, 9 and 12-months  
106 following intervention. All patients gave informed consent for data collected to be  
107 used for research in anonymised fashion prior to inclusion in the UKHR.

108

### 109 *Estimation sample*

110 All consecutive adult patients who entered the registry between 2012-2020 were  
111 assessed for eligibility. Patients with complete, paired EQ-5D-5L and PEM response  
112 scores were eligible for inclusion. As this study aimed to develop cross-sectional  
113 mapping models, all paired EQ-5D-5L and PEM response scores were pooled, giving a  
114 total of 4,052 paired responses. We accounted for data-clustering associated with  
115 repeated observations by calculating robust standard error estimates for reported  
116 model coefficients.

117

### 118 *Source and target measures*

119 The PEM is a widely used hand-specific PROM (Lloyd-Hughes et al., 2019). The PEM  
120 was originally developed as a 10-item PROM with each item scored on a 7-point  
121 Likert scale (Macey et al., 1995). A further item examining the duration of pain was  
122 added in 2001 (Dias et al., 2001). The UKHR captured the original 10-item PEM up  
123 until 2017, after which it began to capture the updated 11-item PEM. The original 10  
124 and updated 11-item PEM are scored from 10-70 and 10-77 respectively, with higher  
125 scores indicating greater disability. To maximise the use of available data, we  
126 included both response sets from the 10 and 11-item PEM in the UKHR. We reverse-

127 scaled PEM responses to improve interpretability, meaning responses to both the 10  
128 and 11-item PEM were rescaled from 0-100 with higher scores indicating better  
129 function.

130

131 The EQ-5D is a generic, preference-based measure of health with five domains:  
132 mobility, self-care, usual activities, pain and discomfort and anxiety and depression.  
133 The EQ-5D was originally developed on a three-point Likert scale (EQ-5D-3L) (Dolan,  
134 1997). Recently, a five-level response PROM (EQ-5D-5L) was developed (Herdman et  
135 al., 2011). This comprises the same health domains however these are assessed on  
136 a five-point Likert scale. The health states described by the EQ-5D-5L have been  
137 valued by the UK population (Devlin et al., 2018). The UKHR captures the EQ-5D-5L;  
138 associated utilities were calculated with the UK value set using the R package 'eq5d.'

139

140 *Models*

141 Transfer to utility (TTU) models were evaluated in the present study. These models,  
142 also known as direct utility mapping models, aim to predict EQ-5D utilities from total  
143 PEM response scores. The distribution of EQ-5D utilities was examined and  
144 regression techniques were selected accordingly, see Table 1, (Hernandez and  
145 Wailoo, 2015). The distribution of EQ-5D scores observed in the present study is in  
146 line with previously reported data across a range of health states (including those  
147 experienced by patients with conditions affecting the upper limb) and demonstrates  
148 notable key characteristics, including: a mass of observations at full health (utility  
149 score of 1), a gap between full and intermediate health states and a non-normal  
150 distribution (Hernandez Alava et al., 2018; Valsamis et al., 2023).

151 Given these distributional properties, we considered multiple modelling approaches.

152 Censored regression (Tobit) was employed to address the upper bound of EQ-5D  
153 utilities at 1, ensuring that predicted values remained within a plausible range.

154 However, given the clear gap between full and intermediate health states, a two-part

155 model was also used. This approach incorporated an initial logistic regression step to  
156 classify patients with a utility score of 1 separately from those with lower scores,  
157 followed by a linear regression for patients with utilities below 1. This strategy  
158 accounted for the clustering of data at full health while improving prediction  
159 accuracy for those with intermediate health states. Additionally, an adjusted limited  
160 dependent variable mixture model was applied to account for the non-normal EQ-5D  
161 distribution, mass of observations at 1 and gap between full and intermediate health  
162 states. The observed distribution of EQ-5D response data and subsequent model  
163 selection is in keeping with contemporary EQ-5D mapping studies (Dakin et al.,  
164 2018), see Table 1 for full model descriptions. We did not evaluate the effect of  
165 covariates such as age, gender, condition and intervention to improve parsimony.

#### 166 *Validation*

167 An external validation dataset was not used in the present study due to lack of data  
168 availability. Instead, we randomly split our dataset into training (80% of total data)  
169 and testing (20% of total data) samples. Models were developed using the training  
170 dataset, model fit was then assessed using the testing dataset. We used bootstrap  
171 resampling to measure model stability through a 1000-fold repeated random split  
172 (Henderson, 2005). This means our dataset was randomly split 1000 times into  
173 training and testing sets; each time our models were developed and assessed on  
174 different datasets. We then calculated overall model performance across the 1000  
175 datasets.

176

177 We assessed Mean Absolute Error (MAE), Mean Square Error (MSE) and Root Mean  
178 Square Error (RMSE) between observed and predicted EQ-5D utility scores as primary  
179 measures of model performance. We averaged measures of model performance  
180 across the 1000 testing datasets. All statistical analyses were undertaken using R (R  
181 Core Team, 2013).

182

183

184

185

186

## 187 **RESULTS**

188 The final dataset included a total of 4503 paired EQ-5D-5L and PEM responses from  
189 2043 patients. There were missing data (defined as incomplete matched EQ-5D-5L  
190 and PEM responses) for 2611 patients. Of the included patients, 72% were diagnosed  
191 with base of thumb osteoarthritis (n= 1472), 2% were diagnosed with cubital tunnel  
192 syndrome (n = 35) and 26% were diagnosed with Dupuytren's disease (n= 536). The  
193 median age of included patients was 65 years (52 to 78 years); 36% of patients were  
194 male (n= 744) and 64% were female (n= 1299).

195

196 The distribution of EQ-5D-5L index and reverse scaled PEM scores are demonstrated  
197 in Figures 1 and 2, respectively. The distribution of EQ-5D-5L index values  
198 demonstrates a mass of observations at 1 (equivalent to perfect health) with a gap  
199 in utility values between full (utility score 1) and intermediate (utility score 0.95)  
200 health states in line with the UK EQ-5D-5L valuation tariff (Devlin et al., 2018). The  
201 distribution of reverse scaled PEM scores is approximately symmetric with a slight  
202 left skew (absolute value skewness -0.275). Both EQ-5D-5L utility and reverse-scaled  
203 PEM scores demonstrated clustering by condition, see Figures 3 and 4.

204

205 Mean and standard deviation for each performance measure across the testing data  
206 subsets is presented in Table 2. The tobit (censored regression) model had the lowest  
207 MAE (0.127) followed by the two-part model (0.128). The Adjusted Limited  
208 Dependent Variable Mixture Model (ALDVMM) had the highest MAE (0.132), whereas  
209 the Tobit had the highest RMSE (0.184), see Table 2.

## 210 **DISCUSSION**

211 This study presents a range of transfer-to-utility mapping algorithms to derive health  
212 state utility values from the PEM, a commonly used hand-specific PROM. Mapping  
213 algorithms were derived using routinely collected data from patients undergoing  
214 intervention for elective hand conditions as part of the UKHR.

215

216 Despite the use of a large national database in conjunction with sophisticated  
217 regression techniques, the population-level prediction error of our best performing  
218 models is clinically relevant. Our best performing model, the Tobit censored  
219 regression model, had a mean absolute error of 0.127. Consider a patient with an  
220 actual EQ-5D utility score of 0.5. An error of 0.127 could produce an HSUV prediction  
221 of 0.373 or 0.627. Contextually, this represents the difference between an individual  
222 with severe pain and severe depression and an individual with moderate pain and  
223 moderate mobility problems (Devlin et al., 2018). Comparative model performance  
224 was not consistent across different performance metrics (MAE and RMSE), with the  
225 Tobit model having the lowest MAE whilst the cubic polynomial model had the lowest  
226 RMSE. This is likely due to differences in residual size and differences in error  
227 penalisation between RMSE and MAE. The overall model prediction accuracy is in  
228 keeping with similar mapping studies. Valsamis *et al.*, report comparable mapping  
229 algorithm prediction accuracy in their study which used the Oxford Shoulder Score as  
230 their source measure: MAE range 0.136 to 0.156 (Valsamis et al., 2023).

231 Interestingly, Valsamis et al. report a higher MAE for complex, bespoke EQ-5D  
232 mapping models (namely the ALDVMM) as compared to simple linear regression  
233 models. This mirrors the results of our study where bespoke EQ-5D mapping  
234 algorithms had a higher degree of error compared to simple linear regression  
235 models. This may be due to the fact that mapping does not account for variables  
236 which effect overall quality of life that are not captured by the clinical measure of  
237 interest. Further, the EQ-5D may not be appropriate for all conditions and patient

238 cohorts of interest. In such circumstances, the development of condition-specific  
239 preference-based measures should be considered.

240

241 In contrast to Valsamis *et al.*, the present study solely focused on EQ-5D-5L derived  
242 utility values. This is because the UK Hand Registry only collects EQ-5D-5L data from  
243 respondents. In their 2019 position statement, NICE recommend that the EQ-5D-3L  
244 be used for reference case-analyses due to concerns regarding the quality and  
245 reliability of the data used in the valuation study ((NICE), 2019). Where primary data  
246 is collected using the EQ-5D-5L, NICE advocate the use of a mapping algorithm to  
247 derive EQ-5D-3L utility values. We opted to develop mapping algorithms using the 5L  
248 value set available in the UKHR as previous work has demonstrated comparable  
249 model performance using a primary EQ-5D-5L value set and EQ-5D-3L crosswalk  
250 values (Valsamis *et al.*, 2023).

251

252 The present study demonstrates that the PEM can be mapped to the EQ-5D-5L using  
253 transfer-to-utility mapping. Response mapping aims to predict the responses to  
254 individual EQ-5D questions rather than the resultant HSUV. Using country specific  
255 value sets, HSUVs can then be determined from the mapped EQ-5D health state.  
256 Response mapping aims to address the inherent limitations of transfer-to-utility  
257 mapping, however estimating response mapping models is computationally intensive  
258 and requires access to complete EQ-5D response data (Hernández Alava *et al.*,  
259 2020). Future mapping studies should investigate whether the PEM can be accurately  
260 mapped to EQ-5D-3L index values using response mapping. A range of hand-specific  
261 PROMs have been developed. Future work should also ascertain the accuracy of  
262 mapping algorithms developed using a range of hand-specific PROMs.

263

264 The clinically relevant error margin demonstrated in the present study may suggest  
265 that mapping the PEM onto generic preference-based measures may not be

266 appropriate. The assumption that the EQ-5D is an appropriate measure for use in  
267 patients with hand conditions is questionable. Previous work has shown that the EQ-  
268 5D is not responsive to clinical deterioration in patients with rheumatoid arthritis  
269 (Payakachat et al., 2015). The poor responsiveness of generic preference-based  
270 measures such as the EQ-5D may mean that interventions for hand conditions are  
271 undervalued in cost-effectiveness analyses. This risks interventions being labelled ‘of  
272 limited clinical value’ when compared to treatments for other conditions such as  
273 knee arthritis. One solution to the poor responsiveness of generic preference-based  
274 measures is the use of condition-specific preference-based measures (CS-PBMs). CS-  
275 PBMs can be derived from existing PROMs which pose more relevant questions to the  
276 target population using established methods (Brazier et al., 2012). Future work  
277 should aim to develop a value set for an established hand-specific PROM. This would  
278 enable utility values to be determined for health states described by the hand-  
279 specific PROM and overcome the limitations of generic preference-based measures in  
280 hand surgery.

281

282 The present study is not without limitations. We did not have a separate external  
283 validation dataset and instead chose to perform bootstrap validation with 1000-fold  
284 test-training samples and validating models across these splits. Given that error is  
285 likely to increase in an external validation sample, this limitation does not detract  
286 from the principle study findings. We did not examine the effect of additional  
287 variables such as age and gender to improve the generalisability of models to  
288 datasets where such data are not available.

289

290 Our findings are applicable across surgical sub-specialties. We have demonstrated  
291 that responses to domain-specific PROMs can be mapped to EQ-5D utilities, albeit  
292 with a clinically relevant margin of error. The principal advantage of mapping is  
293 increased availability of data for cost-utility analyses in the absence of primary EQ-

294 5D data. However, analysts must interpret the results of mapped utility values with  
295 caution given the additional uncertainty associated with having to derive utility  
296 scores using responses to distinct outcome assessment tools. Analysts must consider  
297 whether the EQ-5D is an appropriate measure in the cohort of interest. This is of  
298 particular relevance in hand surgery where the impact of hand conditions may not  
299 impair health domains measured by the EQ-5D such as mobility. However, general  
300 surgical pathologies (such as colorectal cancer) may be associated with greater  
301 general disability and subsequent impairments in quality of life may be better  
302 represented in EQ-5D scores, meaning mapping may be appropriate. Where this is  
303 not the case, NICE advocate the use of condition-specific preference-based measures  
304 for technology appraisal (NICE, 2013). Efforts should therefore be concentrated on  
305 the development of condition-specific preference-based measures in relevant  
306 cohorts, rather than the development of mapping algorithms.

307

308 In conclusion, the mapping models developed and evaluated in this study enable  
309 decision analysts to obtain EQ-5D-5L HSUVs from the PEM where primary EQ-5D-5L  
310 data are not available. The error margin of our best performing model is clinically  
311 significant. Future work should aim to develop a value set for hand-specific PROMs.

312

### 313 **FIGURE LEGENDS**

314

315 **Figure 1:** EQ-5D-5L utility distribution

316 **Figure 2:** Reverse scaled PEM distribution

317 **Figure 3:** Density plot of EQ-5D-5L utilities stratified by condition

318 **Figure 4:** Density plot of reverse scaled PEM scores stratified by condition

319

320

321

## 322 REFERENCES

- 323 (NICE) NIfHaCE. Position statement on use of the eq-5d-5l value set for england (updated  
324 october 2019). 2019. [https://www.nice.org.uk/about/what-we-do/our-programmes/nice-](https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l)  
325 [guidance/technology-appraisal-guidance/eq-5d-5l](https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l) (26/05/2024).
- 326 Barr B, Bambra C, Whitehead M. The impact of nhs resource allocation policy on health  
327 inequalities in england 2001-11: Longitudinal ecological study. *Bmj*. 2014, 348: g3231.
- 328 Brazier JE, Rowen D, Mavranzouli I et al. Developing and testing methods for deriving  
329 preference-based measures of health from condition-specific measures (and other  
330 patient-based measures of outcome). *Health Technol Assess*. 2012, 16: 1-114.
- 331 Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal of studies mapping from  
332 quality of life or clinical measures to eq-5d: An online database and application of the  
333 maps statement. *Health Qual Life Outcomes*. 2018, 16: 31.
- 334 Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life:  
335 An eq-5d-5l value set for england. *Health Econ*. 2018, 27: 7-22.
- 336 Dias JJ, Bhowal B, Wildin CJ, Thompson JR. Assessing the outcome of disorders of the  
337 hand. Is the patient evaluation measure reliable, valid, responsive and without bias? *J*  
338 *Bone Joint Surg Br*. 2001, 83: 235-40.
- 339 Dolan P. Modeling valuations for euroqol health states. *Med Care*. 1997, 35: 1095-108.
- 340 Henderson AR. The bootstrap: A technique for data-driven statistics. Using computer-  
341 intensive analyses to explore experimental data. *Clin Chim Acta*. 2005, 359: 1-26.
- 342 Herdman M, Gudex C, Lloyd A et al. Development and preliminary testing of the new five-  
343 level version of eq-5d (eq-5d-5l). *Qual Life Res*. 2011, 20: 1727-36.
- 344 Hernandez Alava M, Wailoo A, Grimm S et al. Eq-5d-5l versus eq-5d-3l: The impact on  
345 cost effectiveness in the united kingdom. *Value Health*. 2018, 21: 49-56.
- 346 Hernández Alava M, Wailoo A, Pudney S, Gray L, Manca A. Mapping clinical outcomes to  
347 generic preference-based outcome measures: Development and comparison of methods.  
348 *Health Technol Assess*. 2020, 24: 1-68.
- 349 Hernandez M, Wailoo A. Fitting adjusted limited dependent variable mixture models to  
350 eq-5d. *Stata Journal*. 2015, 15: 737-50.
- 351 Lizan Tudela LV, Paz S, Rodriguez JM, Gonzalez P. Quality adjusted life years (qalys) in  
352 economic evaluations of health technologies in spain: A review of the 2003-2009  
353 literature. *Value in Health*. 2009, 12.
- 354 Lloyd-Hughes H, Geoghegan L, Rodrigues J et al. Systematic review of the use of patient  
355 reported outcome measures in studies of electively-managed hand conditions. *J Hand*  
356 *Surg Asian Pac Vol*. 2019, 24: 329-41.
- 357 Macey AC, Burke FD, Abbott K et al. Outcomes of hand surgery. *Journal of Hand Surgery*.  
358 1995, 20: 841-55.
- 359 NICE. Nice process and methods guides. In: *Guide to the methods of technology appraisal*  
360 2013, London, National Institute for Health and Care Excellence (NICE)

361 Copyright © 2013 National Institute for Health and Clinical Excellence, unless otherwise  
362 stated. All rights reserved., 2013.

363 Payakachat N, Ali MM, Tilford JM. Can the eq-5d detect meaningful change? A systematic  
364 review. *Pharmacoeconomics*. 2015, 33: 1137-54.

365 Petrou S, Rivero-Arias O, Dakin H et al. The maps reporting statement for studies  
366 mapping onto generic preference-based outcome measures: Explanation and elaboration.  
367 *Pharmacoeconomics*. 2015, 33: 993-1011.

368 R Core Team R. R: A language and environment for statistical computing. 2013.

369 Raisch DW. Understanding quality-adjusted life years and their application to  
370 pharmacoeconomic research. *Ann Pharmacother*. 2000, 34: 906-14.

371 Valsamis EM, Beard D, Carr A et al. Mapping the oxford shoulder score onto the eq-5d  
372 utility index. *Qual Life Res*. 2023, 32: 507-18.

373

374

375